Elevated serum chemerin concentrations are associated with renal dysfunction in type 2 diabetic patients

Diabetes Research and Clinical Practice

Volumn 91, Issue 2, 2011, Pages 159-163

  Hu, Wenchao ^a   Feng, Ping ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

Chemerin; Creatinine clearance; Diabetic rephropathy; Renal function; Type 2 diabetes

Indexed keywords

ADIPOCYTOKINE; C REACTIVE PROTEIN; CHEMERIN; CREATININE; NITROGEN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; UREA;

ADULT; AGE; ALBUMIN BLOOD LEVEL; ALBUMINURIA; ARTICLE; BLOOD LEVEL; BODY MASS; CHEMERIN BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIABETIC NEPHROPATHY; DISEASE MARKER; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MICROALBUMINURIA; NON INSULIN DEPENDENT DIABETES MELLITUS; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL;

ADULT; CHEMOKINES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; HUMANS; KIDNEY; KIDNEY FUNCTION TESTS; MALE; MIDDLE AGED;

EID: 79952042551     PISSN: 01688227     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.diabres.2010.11.016     Document Type: Article

References (19)

1. Goralski K.B., McCarthy T.C., Hanniman E.A., Zabel B.A., Butcher E.C., Parlee S.D., et al. Chemerin, a novel adipokine that regulates adipogenesis and adipocyte metabolism. J Biol Chem 2007, 282:28175-28188.
2. Bozaoglu K., Bolton K., McMillan J., Zimmet P., Jowett J., Collier G., et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome. Endocrinology 2007, 148:4687-4694.
3. Bozaoglu K., Segal D., Shields K.A., Cummings N., Curran J.E., Comuzzie A.G., et al. Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab 2009, 94:3085-3088.
4. Sell H., Laurencikiene J., Taube A., Eckardt K., Cramer A., Horrighs A., et al. Chemerin is a novel adipocyte-derived factor inducing insulin resistance in primary human skeletal muscle cells. Diabetes 2009, 58:2731-2740.
5. Tan B.K., Chen J., Farhatullah S., Adya R., Kaur J., Heutling D., et al. Insulin and metformin regulate circulating and adipose tissue chemerin. Diabetes 2009, 58:1971-1977.
6. Remuzzi G., Schieppati A., Ruggenenti P. Clinical practice Nephropathy in patients with type 2 diabetes. N Engl J Med 2002, 346:1145-1151.
7. De Cosmo S., Minenna A., Ludovico O., Mastroianno S., Di Giorgio A., Pirro L., et al. Increased urinary albumin excretion, insulin resistance, and related cardiovascular risk factors in patients with type 2 diabetes: evidence of a sex-specific association. Diabetes Care 2005, 28:910-915.
8. Pfau D., Bachmann A., Lössner U., Kratzsch J., Blüher M., Stumvoll M., et al. Serum levels of the adipokine chemerin in relation to renal function. Diabetes Care 2010, 33:171-173.
9. American Diabetes Association Nephropathy in diabetes (position statement). Diabetes Care 2004, 27:S79-S83.
10. Palatini P., Benetti E., Zanier A., Santonastaso M., Mazzer A., Cozzio S., et al. Cystatin C as predictor of microalbuminuria in the early stage of hypertension. Nephron Clin Pract 2009, 113:c309-314.
11. Weigert J., Neumeier M., Wanninger J., Filarsky M., Bauer S., Wiest R., et al. Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf) 2010, 72:342-348.
12. Saraheimo M., Forsblom C., Thorn L., Wadén J., Rosengård-Bärlund M., Heikkilä O., et al. Serum adiponectin and progression of diabetic nephropathy in patients with type 1 diabetes. Diabetes Care 2008, 31:1165-1169.
13. Murata M., Saito T., Otani T., Sasaki M., Ikoma A., Toyoshima H., et al. An increase in serum retinol-binding protein 4 in the type 2 diabetic subjects with nephropathy. Endocr J 2009, 56:287-294.
14. Grundy S.M., et al. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004, 109:433-438.
15. Lehrke M., Becker A., Greif M., Stark R., Laubender R.P., von Ziegler F., et al. Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol 2009, 161:339-344.
16. Stejskal D., Karpisek M., Hanulova Z., Svestak M. Chemerin is an independent marker of the metabolic syndrome in a Caucasian population-a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2008, 152:217-221.
17. Schneider J.G., von Eynatten M., Schiekofer S., Nawroth P.P., Dugi K.A. Low plasma adiponectin levels are associated with increased hepatic lipase activity in vivo. Diabetes Care 2005, 28:2181-2186.
18. Yannakoulia M., Yiannakouris N., Blüher S., Matalas A.L., Klimis-Zacas D., Mantzoros C.S. Body fat mass and macronutrient intake in relation to circulating soluble leptin receptor, free leptin index, adiponectin, and resistin concentrations in healthy humans. J Clin Endocrinol Metab 2003, 88:1730-1736.
19. Aronson D., Mittleman M.A., Burger A.J. Elevated blood urea nitrogen level as a predictor of mortality in patients admitted for decompensated heart failure. Am J Med 2004, 116:466-473.